Latest News

A new study led by Yale researchers uncovers a new cellular process that links the metabolism of vitamin B5 to the ability of fungi to detoxify drugs. These findings represent a significant leap in our understanding of fungal resistance mechanisms and herald new treatment possibilities for combating resilient fungal strains, with far-reaching implications for patients worldwide.

The Colton Center for Autoimmunity at Yale is pleased to announce the eleven 2024 Yale projects selected for their promising research in autoimmunity and allergic diseases. In addition to grant funding, Colton Center awardees receive mentorship, access to industry expertise, and feedback on their potential commercialization.

The American Thoracic Society (ATS) presented Carolyn Rochester, MD, FCCP, with the Assembly on Pulmonary Rehabilitation Lifetime Achievement Award at the ATS International Conference in late May 2024 in San Diego.

The NIH/NIDDK P30 Liver Center grant provides for the annual submission of pilot projects ($40,000 direct costs each) from both Liver Center and non-Liver Center investigators.

Bubu Banini, MD, PhD, assistant professor of medicine (digestive diseases) at Yale School of Medicine, discusses signs and symptoms of liver disease.

In a new study, published in the American Journal of Respiratory and Critical Care Medicine, researchers used single-cell RNA sequencing to measure the gene expressions of individual peripheral blood mononuclear cells in patients with progressive IPF, patients with stable IPF, and lung-disease-free patients. Previously, the researchers had studied bulk samples of these cells but not examined them individually and in detail.

Naftali Kaminski, MD, Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine and chief of Pulmonary, Critical Care, and Sleep Medicine (Yale-PCCSM), recently partnered with the American Thoracic Society (ATS) to launch a new podcast.

Until very recently, no treatment options were available for metabolic-associated steatolic liver disease (MASLD) (previously called non-alcoholic fatty liver disease). The Food and Drug Administration recently approved resmetirom, the first therapy for the more severe form of MASLD, but there remains a need for a generic, affordable treatment option for patients. Bubu Banini, MD, PhD, was recently awarded a $3.05 million R01 grant by the National Institutes of Health (NIH) for a five-year research project to investigate the feasibility of oral digoxin as a treatment option for these patients.